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Abstract
Stephen P. Goff wins the 2005 RETROVIROLOGY prize.
Earlier this year, I announced that Retrovirology  would
inaugurate an annual prize to recognize the achievements
of a deserving mid-career retrovirologist [1]. There are two
reasons why we feel such an award is timely. First, retrovi-
rology is an increasingly robust and important field of sci-
ence. It seems wanting that no award exists to recognize
exclusively excellence in basic retrovirus research. Second,
although there are many scientific prizes and awards, very
few are targeted only to mid-career scientists. In principle,
the awarding of a prize carries two worthy aims. Prizes
reward individuals for past achievements, and prizes also
bring visibility and encourage future advances in particu-
lar research problems/fields. For the latter goal, choosing
an outstanding mid-career individual who is on the peak
of his/her productivity curve and who is poised for many
years of "best" work ahead is more than appropriate.
Hence, while the roster of winners of many awards fre-
quently reads the same as other awards, the RETROVI-
ROLOGY prize intends to highlight fresh scientists for
their ongoing and accelerating research achievements.
A few wealthy international philanthropies frequently
and deservedly capture the limelight with their research
largess. On the other hand, every department Chairman
and Dean of schools recognize the unsung importance of
the many small local donors who fund the student schol-
arships, the travel stipends, and the stop-gap institutional
research grants that keep the daily lifeblood of science
flowing. The inaugural RETROVIROLOGY prize is sup-
ported through a donation from the Ming K. Jeang Foun-
dation, an educational foundation based in Houston,
Texas, which has provided for scholarships at Houston
schools, at the University of Arizona, and at the Johns
Hopkins University School of Medicine. Our inaugural
award is named the M. Jeang RETROVIROLOGY prize.
For 2005, the Editors of Retrovirology selected Stephen P.
Goff as the first recipient of the RETROVIROLOGY prize.
Stephen Goff is the Higgins Professor of Biochemistry and
Molecular Biophysics at the College of Physicians and Sur-
geons, Columbia University, USA. He was one of the first
investigators to clone a functional copy of a retroviral
genome, and to use recombinant DNA methods to study
viral replication. Over the last two decades Dr. Goff has
developed and exploited the Moloney murine leukemia
virus as a genetic system. One of his most important
results was the definition of the functional domains of the
viral pol gene, and, especially, the seminal discovery of a
viral function, now termed the integrase function,
required for the integration of viral DNA into the host
genome. Dr. Goff was also the first to develop plasmids
that express enzymatically active reverse transcriptase (RT)
of both mouse and human viruses. Fine-structure muta-
tional analysis proved that reverse transcriptase contains
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separate, and separable, DNA polymerase and RNAse H
domains.
Dr. Goff has used the yeast two-hybrid system to detect
and characterize protein-protein interactions between
viral proteins, and also between viral and host gene prod-
ucts. He discovered that cyclophilin A, a host prolyl iso-
merase, binds specifically to the HIV-1 Gag, and regulates
both infectivity and escape from host restrictions. Dr. Goff
has additionally pioneered the use of somatic cell genetics
to identify host genes that affect retrovirus replication. He
has identified a novel zinc-finger antiviral protein (ZAP)
which directly binds specific sequences in viral RNAs in
the cytoplasm and targets these RNAs for degradation.
Goff has also been active in the study of retroviral onco-
genes, notably the v-abl  gene carried by the Abelson
murine leukemia virus. Goff was the first to prepare
molecular clones of the viral genome and the cellular pro-
tooncogene, and to map the structure and chromosomal
location of c-abl. The Goff laboratory has identified sev-
eral novel Abl-binding proteins that regulate Abl signal-
ling. He has shown that one such bridging molecule, PST-
PIP1, directs phosphatases to act on Abl and thereby neg-
atively regulate its tyrosine kinase activity.
In choosing the prize winner, the Editors considered more
than just scientific excellence, and sought to identify the
rare individual who is both an outstanding researcher and
a selfless mentor. In the big picture of science, the suc-
cesses of a scientist's students and students-of-students in
generations hence likely hold much larger impact than
even the most stellar singular career. Fittingly, at mid-
career, Stephen Goff has already trained several highly
successful scientists.
To understand Steve better as a scientist and a teacher, I
had an opportunity in a question-and-answer session to
solicit his views on several issues of interest. His answers
to my questions are presented below.
KTJ: Did you always want to be a scientist or was there
something else that you wanted to do when you were
young?
SPG: I knew I wanted to do science very early in life, beginning
with grade school. My father was a contractor, carpenter, boat-
builder, mechanic, and clock repairman, and had a fabulous
workshop. I grew up taking machinery apart and putting it back
together and have always enjoyed watching complicated
machines at work. I was particularly fascinated by chemistry in
high school and with the idea that molecules were just very
small machines. My older brother Chris went into molecular
biology before me, and it was completely natural to me to follow
in his footsteps. I'm still fascinated with these molecular
machines that support our lives.
KTJ: What attracted you to go into retrovirus research?
SPG: I was first attracted to work on the small DNA viruses at
Stanford as a graduate student in Paul Berg's lab because of the
amazing techniques to manipulate DNA that were just being
developed – SV40 provided the first chance to isolate and
manipulate the complete genome of a simple organism (even
before recombinant DNA). I liked the notion that one could
write or modify a genetic program, much as one could write a
computer program, and watch the results in action. As I looked
around for possible subjects of study for my postdoc, I was very
attracted by the RNA tumor viruses and their complex life cycle,
at that time only known in outline, and their potential for gene
therapy. A meeting with David Baltimore in 1977 convinced
me that his lab would be an amazing place to apply recom-
binant DNA methods to the study of these viruses, and this
cemented my choice. I've been working on these viruses ever
since.
KTJ: Who had the most influence on your career and how?
SPG: Many people have shaped my thinking and the direction
of my research. Paul Berg taught me how to design experiments,
how to think carefully and fully about data, and how to present
results clearly in writing and at meetings. David Baltimore
taught me how to be incisive and efficient at work, and to focus
on the most important issues – and to be bold. Many people in
the field have been and continue to serve as role models:
Howard Temin, Frank Lilly, Harold Varmus, and John Coffin
have been particularly important.
KTJ: What do you see as some of the important questions
in retrovirology in the near and long term future?
SPG: I think one obvious growth area is the interaction of
viruses with the host. New tools – mainly genetic ones – have
made it possible to identify and characterize the interactions of
viral proteins with specific cellular machinery, and to learn how
the viruses exploit that machinery for intracellular movement,
macromolecular synthesis, and assembly. Another related area
is the innate or intrinsic immunity to retrovirus infection that
is just now being uncovered. I think one of the original justifi-
cations for the study of viruses – their ability to spotlight excit-
ing or critical aspects of cell biology – is now being powerfully
validated.
KTJ: What do you consider as your most important scien-
tific contribution, and what is currently the most exciting
research in your laboratory?
SPG: Broadly, I would suppose that my major contribution has
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system. Within that area, I think the characterizations of viral
mutants defective in the protease, the integrase, and p12 gag
are likely the most important results, both for their implications
for basic virology and for the applied aspects of antiviral drug
development. I am also proud of cloning the v-abl oncogene and
c-abl protooncogene, which has ultimately led to the antitumor
drug Gleevec, and of helping Liz Robertson in the development
of mouse knock-out technology used in the isolation of abl KO
mice.
KTJ: Young scientists who are yet established can some-
times feel that their manuscripts and/or their grants have
been unfairly reviewed. What is your advice to them?
SPG: Many of us, young and old, often feel that our work has
been unfairly reviewed and deserves reconsideration. It is
important to develop a thick skin and keep trying – both in
terms of resubmissions and in submitting to alternative jour-
nals. I encourage budding authors to rebut negative reviews as
directly as possible and to request that the editors stand in
judgement of the issues. When those avenues fail for a given
journal, I would encourage young scientists to move on to the
next logical journal, and given the expanding number of new
journals there is little chance that an important result will go
unpublished through prejudice or bias. I have great faith in the
peer review process. In terms of grant reviews, competition is
now at an almost unprecedented high. For new investigators
working to establish their laboratories, this is a very difficult
time to find funding, but here too persistence is key. Don't be
discouraged and keep applying – quality will be rewarded.
KTJ: There are great scientists who do great science, and
then there are great scientists who do great science and
train great scientists. What are your secrets to training
great scientists?
SPG: I hope that I will be remembered as someone who trained
a large number of active and productive scientists – at last count
I have graduated 25 students and trained about the same
number of fellows. I try to give my students considerable free-
dom to explore new avenues, to fail and succeed, and so to learn
by experience what is worthwhile and what is too risky. I try to
encourage optimism, self-motivation, and give some sense of the
excitement we all have in what we do.
KTJ: If one remembers you by the scientists that you have
trained, who would you wanted to be remembered by and
why?
SPG: I suppose one is most attached to the earliest people in the
lab, those who helped establish us as an ongoing concern. In my
case, the list would have to include such early students as John
Colicelli, Naoko Tanese, and Pam Schwartzberg, and my first
postdoc Monica Roth, all of whom are running active labs
today. All are superb scientists and I consider myself blessed to
have had them working with me – I would be proud to be
remembered as having helped train them. But any such list is
wildly incomplete, and I feel the same way about everyone who
has passed through my laboratory. All are like family.
KTJ: How do you see your role with your former trainees
after they have left your lab?
SPG: I feel it is critically important to set my outgoing people
on a productive course, with at least one project for the fellows
immediately ready to go – with the hope of quick and easy
experiments. The pressure for rapid publications from a new
laboratory is so intense today that successful trainees need to hit
the ground running and do meaningful experiments from their
first day in their new home. We have established a pattern
where outgoing fellows are given the opportunity to exploit a
new gene that they have identified in my lab and can work to
develop an understanding of its mode of action, its partners,
and its significance in the life cycle. I am always thrilled to read
new papers from my former trainees as they expand the bound-
aries of virology.
KTJ: Someone told me once that every 10 years he would
like to reinvent himself. What do you see yourself doing
10 years from now that might be different from what you
are doing today? When do you think you would stop
doing research and how will you know when the time is
right?
SPG: I would be perfectly happy to be doing science ten years
from now in much the same way I am now – realizing that the
actual science we do is changing every day. The great thing
about our field is how rapidly technology opens new doors and
expands our capabilities, and I like to be early in applying new
methods. I think I will stop running a laboratory when I no
longer feel able to contribute to technology development, to
effectively apply new methods to problems, and to be nimble.
My students will probably let me know.
KTJ: In my office there is a quotation by Edmond Burke
'All that is necessary for the triumph of evil is that good
men do and say nothing'. If there is one thing that you
think needs to be said or done in science (or in society at
large), what would that be?
SPG: A major problem for scientists is that the power and con-
tributions of science to our society are grossly underappreciated
by the nonscientific public at large. The gap between scientists
and nonscientists is growing wider and is undercutting support
for our work. We must fight this trend and point out to Con-
gress all the benefits of their support. We as scientists must try
to communicate the value and excitement of our work to our
nonscientific friends.Publish with BioMed Central    and   every 
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KTJ: Would you want your children to become basic
research scientists? Why or why not?
SPG: I think this is a wonderful time to enter the field of basic
research, with the most amazing opportunities for new findings
just coming available – even if funding in the next few years
looks to be tight. But being a successful basic scientist requires
a love of experimentation and an innate drive to learn about the
way things work, and it is a demanding life. Neither of my two
children is inclined toward basic science, and without that nat-
ural bent I would never push them into my field. I want them
to be successful and happy in whatever way they choose to con-
tribute to society.
KTJ: With the understanding that it will be a long time in
the future, what would you like your headstone to read?
SPG: Maybe "He made it work;" or "He fixed it;" or"He liked
solving puzzles."
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